

**In MEDLINE im Jahr 2008 gelistete Publikationen (n=68) von wissenschaftlichen Mitarbeiterinnen und Mitarbeitern der Frauenklinik (Klinik und Forschung) der TU München und/oder mit Impaktfaktor von 2007 (Stand: 04.03.2009)**

(alphabetisch nach Erstautor sortiert, Klinikautoren fett)

Definition analog zu LOM: Medline-gelistet und/oder Impaktfaktor, in 2008 voll publiziert, nicht *in print*-Status, nicht *Online* publiziert, keine Abstrakts

1. **Anneck K, Schmitt M, Euler U**, Zerm M, **Paepke D, Paepke S**, von Minckwitz G, Thomssen C, **Harbeck N**. [uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial](#). Adv Clin Chem. 2008;45:31-45. **IF=2,364**
2. Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler RK, Vermold B, Engel C, **Meindl A**, Arnold N, Hofmann W, Sutter C, Niederacher D, Deissler H, Caldes T, Kämpjärvi K, Nevanlinna H, Simard J, Beesley J, Chen X; Kathleen Cuninghame Consortium for Research into Familial Breast Cancer, Neuhausen SL, Rebbeck TR, Wagner T, Lynch HT, Isaacs C, Weitzel J, Ganz PA, Daly MB, Tomlinson G, Olopade OI, Blum JL, Couch FJ, Peterlongo P, Manoukian S, Barile M, Radice P, Szabo CI, Pereira LH, Greene MH, Rennert G, Lejbkowitz F, Barnett-Griness O, Andrulis IL, Ozcelik H; OCGN, Gerdes AM, Caligo MA, Laitman Y, Kaufman B, Milgrom R, Friedman E; Swedish BRCA1 and BRCA2 study collaborators, Domchek SM, Nathanson KL, Osorio A, Llort G, Milne RL, Benítez J, Hamann U, Hogervorst FB, Manders P, Ligtenberg MJ, van den Ouweland AM; DNA-HEBON collaborators, Peock S, Cook M, Platte R, Evans DG, Eeles R, Pichert G, Chu C, Eccles D, Davidson R, Douglas F; EMBRACE, Godwin AK, Barjhoux L, Mazoyer S, Sobol H, Bourdon V, Eisinger F, Chompret A, Capoulade C, Bressac-de Paillerets B, Lenoir GM, Gauthier-Villars M, Houdayer C, Stoppa-Lyonnet D; GEMO, Chenevix-Trench G, Easton DF; CIMBA. [Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers](#). Am J Hum Genet. 2008 Apr;82(4):937-48. **IF=11,092**
3. Beaufort N, Wojciechowski P, Sommerhoff CP, Szmyd G, Dubin G, Eick S, Kellermann J, **Schmitt M**, Potempa J, **Magdolen V**. [The human fibrinolytic system is a target for the staphylococcal metalloprotease aureolysin](#). Biochem J. 2008 Feb 15;410(1):157-65. **IF=4,009**
4. Beer AJ, **Niemeyer M**, Carlsen J, Sarbia M, Nährig J, Watzlowik P, Wester HJ, **Harbeck N**, Schwaiger M. [Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET](#). J Nucl Med. 2008 Feb;49(2):255-9. **IF=5,915**
5. Biermann JC, Holzscheiter L, Kotzsch M, Luther T, **Kiechle-Bahat M**, Sweep FC, Span PN, **Schmitt M, Magdolen V**. [Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA](#). Int J Mol Med. 2008 Feb;21(2):251-9. **IF=1,847**
6. Blechschmidt K, Sassen S, **Schmalfeldt B**, Schuster T, Höfler H, Becker KF. [The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients](#). Br J Cancer. 2008 Jan 29;98(2):489-95. **IF=4,635**
7. Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, Bilezikian J, Kerzberg EM, Johnson S, Zanchetta J, Grobbee DE, Seifert W, Eastell R; LIFT Trial Investigators. [The effects of tibolone in older postmenopausal women](#). N Engl J Med. 2008 Aug 14;359(7):697-708. **IF=52,589 \***
8. Debela M, Beaufort N, **Magdolen V**, Schechter NM, Craik CS, **Schmitt M**, Bode W, Goettig P. [Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7](#). Biol Chem. 2008 Jun;389(6):623-32. **IF=2,840**
9. Diehl P, Schauwecker J, Mittelmeier W, **Schmitt M**. [High hydrostatic pressure, a novel approach in orthopedic surgical oncology to disinfect bone, tendons and cartilage](#). Anticancer Res. 2008 Nov-Dec;28(6B):3877-83. **IF=1,414**
10. Engert S, Wappenschmidt B, Betz B, Kast K, Kutsche M, Hellebrand H, Goecke TO, **Kiechle M**, Niederacher D, Schmutzler RK, **Meindl A**. [MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases](#). Hum Mutat. 2008 Jul;29(7):948-58. **IF=6,273**
11. Fichter MA, Dornseifer U, Henke J, **Schneider KT**, Kovacs L, Biemer E, Bruner J, Adzick NS, Harrison MR, Papadopoulos NA. [Fetal spina bifida repair--current trends and prospects of intrauterine neurosurgery](#). Fetal Diagn Ther. 2008;23(4):271-86. **IF=0,844**

12. Fotopoulou C, duBois A, Karavas AN, Trappe R, Aminossadati B, **Schmalfeldt B**, Pfisterer J, Sehoul J; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. [Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.](#) J Clin Oncol. 2008 Jun 1;26(16):2683-9. **IF=15,484**
13. Frank B, Rigas SH, Bermejo JL, Wiestler M, Wagner K, Hemminki K, Reed MW, Sutter C, Wappenschmidt B, Balasubramanian SP, **Meindl A, Kiechle M**, Bugert P, Schmutzler RK, Bartram CR, Justenhoven C, Ko YD, Brüning T, Brauch H, Hamann U, Pharoah PP, Dunning AM, Pooley KA, Easton DF, Cox A, Burwinkel B. [The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study.](#) Breast Cancer Res Treat. 2008 Sep;111(1):139-44. **IF=4,453**
14. Frank B, Wiestler M, Kropp S, Hemminki K, Spurdle AB, Sutter C, Wappenschmidt B, Chen X, Beesley J, Hopper JL; Australian Breast Cancer Family Study Investigators, **Meindl A, Kiechle M**, Slanger T, Bugert P, Schmutzler RK, Bartram CR, Flesch-Janys D, Mutschelknauss E, Ashton K, Salazar R, Webb E, Hamann U, Brauch H, Justenhoven C, Ko YD, Brüning T, Silva Idos S, Johnson N, Pharoah PP, Dunning AM, Pooley KA, Chang-Claude J, Easton DF, Peto J, Houlston R; Gene Environment Interaction and Breast Cancer in Germany Group, Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer Investigators, Australian Ovarian Cancer Study Management Group, Chenevix-Trench G, Fletcher O, Burwinkel B. [Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis.](#) J Natl Cancer Inst. 2008 Mar 19;100(6):437-42. **IF=15,678**
15. Gluz O, Nitz UA, **Harbeck N**, Ting E, Kates R, Herr A, Lindemann W, Jackisch C, Berdel WE, Kirchner H, Metzner B, Werner F, Schütt G, Frick M, Poremba C, Diallo-Danebrock R, Mohrmann S; West German Study Group. [Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.](#) Ann Oncol. 2008 May;19(5):861-70. **IF=4,875**
16. Gohlke-Bärwolf C, **Pildner von Steinburg S**, Kaemmerer H, Regitz-Zagrosek V. [\[Anticoagulation and thrombophilia in pregnancy\]](#) Internist (Berl). 2008 Jul;49(7):779-87. **IF=0,271**
17. Golouh R, Cufer T, Sadikov A, Nussdorfer P, Usher PA, Brünner N, **Schmitt M**, Lesche R, Maier S, Timmermans M, Foekens JA, Martens JW. [The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study.](#) Breast Cancer Res Treat. 2008 Jul;110(2):317-26. **IF=4,453**
18. **Gross E**, Busse B, Riemenschneider M, Neubauer S, **Seck K**, Klein HG, **Kiechle M**, Lordick F, **Meindl A**. [Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients.](#) PLoS ONE. 2008;3(12):e4003. **IF=0,000**
19. **Harbeck N**, Nimrich I, Hartmann A, Ross JS, Cufer T, Grützmann R, Kristiansen G, Paradiso A, Hartmann O, Margossian A, Martens J, Schwobe I, Lukas A, Müller V, Milde-Langosch K, Nährig J, Foekens J, Maier S, **Schmitt M**, Lesche R. [Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.](#) J Clin Oncol. 2008 Nov 1;26(31):5036-42. **IF=15,484**
20. **Harbeck N, Schmitt M**, Vetter M, **Krol J, Paepke D**, Uhlig M, **Paepke S**, Jänicke F, Geurts-Moespot A, von Minckwitz G, Sweep F, Thomssen C. Prospective biomarker trials Chemo N0 and NNBC-3 Europe validate the clinical utility of invasion markers uPA and PAI-1 in node-negative breast cancer. Breast Care 2008;3(Suppl.2):11-15. **IF=0,040**
21. **Harbeck N**. [Never too late: reducing late breast cancer relapse risk.](#) Curr Med Res Opin. 2008 Dec;24(12):3295-305. **IF=2,962**
22. Hoenicka M, **Jacobs VR**, Huber G, Schmid FX, Birnbaum DE. [Advantages of human umbilical vein scaffolds derived from cesarean section vs. vaginal delivery for vascular tissue engineering.](#) Biomaterials. 2008 Mar;29(8):1075-84. **IF=6,262**
23. Holzbach T, Mueller DF, Unbehaun N, **Paepke S**, Giunta RE. [TRAM-flap perfusion across a midline scar 22 years after a lower median laparotomy.](#) J Plast Reconstr Aesthet Surg. 2008 Aug;61(8):992-3. **IF=0,623**

24. Huppertz B, Sammar M, Chefetz I, **Neumaier-Wagner P**, Bartz C, Meiri H. [Longitudinal determination of serum placental protein 13 during development of preeclampsia](#). Fetal Diagn Ther. 2008;24(3):230-6. Epub 2008 Aug 28. **IF=0,844**
25. **Jacobs VR**, Morrison JE Jr. [Comparison of institutional costs for laparoscopic preperitoneal inguinal hernia versus open repair and its reimbursement in an ambulatory surgery center](#). Surg Laparosc Endosc Percutan Tech. 2008 Feb;18(1):70-4. **IF=0,575**
26. **Jacobs VR**: Publication analysis of the international Journal of fertility and womens Medicine from 2004-2006: Topics and their impact. Int J Fertil Womens Med 2008;53(6):188-196. **IF=0,556**
27. Kaltz N, Funari A, Hippauf S, Delorme B, Noël D, Riminucci M, **Jacobs VR**, Häupl T, Jorgensen C, Charbord P, Peschel C, Bianco P, Oostendorp RA. [In vivo osteoprogenitor potency of human stromal cells from different tissues does not correlate with expression of POU5F1 or its pseudogenes](#). Stem Cells. 2008 Sep;26(9):2419-24. **IF=7,531**
28. **Kiechle M**. [\[Human embryonic stem cell research in Germany. The scientific reviewing of applications for the import and use of human embryonic stem cells\]](#) Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2008 Sep;51(9):961-4. **IF=0,000**
29. Knör S, Khrenov A, Laufer B, Benhida A, Grailly SC, Schwaab R, Oldenburg J, Beaufort N, **Magdolen V**, Saint-Remy JM, Saenko EL, Hauser CA, Kessler H. [Efficient factor VIII affinity purification using a small synthetic ligand](#). J Thromb Haemost. 2008 Mar;6(3):470-7. **IF=5,947**
30. Knör S, Sato S, Huber T, Morgenstern A, Bruchertseifer F, **Schmitt M**, Kessler H, Senekowitsch-Schmidtke R, **Magdolen V**, Seidl C. [Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor \(uPAR\) for use in alpha-emitter therapy for disseminated ovarian cancer](#). Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):53-64. **IF=4,101**
31. Kotzsch M, Sieuwerts AM, Grosser M, Meye A, Fuessel S, Meijer-van Gelder ME, Smid M, **Schmitt M**, Baretton G, Luther T, **Magdolen V**, Foekens JA. [Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor](#). Breast Cancer Res Treat. 2008 Sep;111(2):229-40. **IF=4,453**
32. Krainick-Strobel UE, Lichtenegger W, Wallwiener D, Tulusan AH, Jänicke F, Bastert G, Kiesel L, Wackwitz B, **Paepke S**. [Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase II/III trial to investigate optimal duration of preoperative endocrine therapy](#). BMC Cancer. 2008 Feb 26;8:62. **IF=2,709**
33. Leeners B, Stiller R, **Neumaier-Wagner P**, Kuse S, Schmitt A, Rath W. [Psychosocial distress associated with treatment of hypertensive diseases in pregnancy](#). Psychosomatics. 2008 Sep-Oct;49(5):413-9. **IF=2,199**
34. Leyland-Jones BR, Ambrosone CB, Bartlett J, Ellis MJ, Enos RA, Raji A, Pins MR, Zujewski JA, Hewitt SM, Forbes JF, Abramovitz M, Braga S, Cardoso F, **Harbeck N**, Denkert C, Jewell SD; Breast International Group; Cooperative Groups of the Breast Cancer Intergroup of North America (TBCI); American College of Surgeons Oncology Group; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; North Central Cancer Treatment Group; National Cancer Institute of Canada Clinical Trials Group; Southwest Oncology Group; National Surgical Adjuvant Breast and Bowel Project; Radiation Oncology Group; Gynecologic Oncology Group; Children's Oncology Group. [Recommendations for collection and handling of specimens from group breast cancer clinical trials](#). J Clin Oncol. 2008 Dec 1;26(34):5638-44. **IF=15,484**
35. Lindemann K, **Harbeck N**, Lengyel E, Resau JH. [A special key for unlocking the door to targeted therapies of breast cancer](#). ScientificWorldJournal. 2008 Sep 21;8:905-8. **IF=0,000**
36. Loibl S, von Minckwitz G, **Harbeck N**, Janni W, Elling D, Kaufmann M, Eggemann H, Nekljudova V, Sommer H, **Kiechle M**, Kümmel S. [Clinical feasibility of \(neo\)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials](#). Breast Cancer Res. 2008;10(5):R77. **IF=4,371**
37. Lössner D, Abou-Ajram C, Bengel A, **Reuning U**. [Integrin alphavbeta3 mediates upregulation of epidermal growth-factor receptor expression and activity in human ovarian cancer cells](#). Int J Biochem Cell Biol. 2008;40(12):2746-61. **IF=4,009**
38. Luppä PB, **Seifert-Klauss V**. [\[Strategies in laboratory medicine for the endocrinological diagnosis of ovarian disorders\]](#) Ther Umsch. 2008 Sep;65(9):551-7. **IF=0,000**
39. Maroto B, Ye MB, von Lohneysen K, **Schnelzer A**, Knaus UG. [P21-activated kinase is required for mitotic progression and regulates Plk1](#). Oncogene. 2008 Aug 21;27(36):4900-8. **IF=6,440**

40. McKiernan E, O'Brien K, Grebenchtchikov N, Geurts-Moespot A, Sieuwerts AM, Martens JW, **Magdolen V**, Evoy D, McDermott E, Crown J, Sweep FC, Duffy MJ. [Protein kinase Cdelta expression in breast cancer as measured by real-time PCR, western blotting and ELISA](#). Br J Cancer. 2008 Nov 18;99(10):1644-50. **IF=4,635**
41. Morrison JE Jr, **Jacobs VR**. [Laparoscopic preperitoneal inguinal hernia repair using preformed polyester mesh without fixation: prospective study with 1-year follow-up results in a rural setting](#). Surg Laparosc Endosc Percutan Tech. 2008 Feb;18(1):33-9. **IF=0,575**
42. Murphy KE, Hannah ME, Willan AR, Hewson SA, Ohlsson A, Kelly EN, Matthews SG, Saigal S, Asztalos E, Ross S, Delisle MF, Amankwah K, Guselle P, Gafni A, Lee SK, Armson BA; MACS Collaborative Group. [Multiple courses of antenatal corticosteroids for preterm birth \(MACS\): a randomised controlled trial](#). Lancet. 2008 Dec 20;372(9656):2143-51. **IF=28,638 \***
43. Nimmrich I, Sieuwerts AM, Meijer-van Gelder ME, Schwöpe I, Bolt-de Vries J, **Harbeck N**, Koenig T, Hartmann O, Kluth A, Dietrich D, **Magdolen V**, Portengen H, Look MP, Klijn JG, Lesche R, **Schmitt M**, Maier S, Foekens JA, Martens JW. [DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients](#). Breast Cancer Res Treat. 2008 Oct;111(3):429-37. **IF=4,453**
44. Oostendorp RA, Gilfillan S, Parmar A, Schiemann M, Marz S, **Niemeyer M**, Schill S, Hammerschmid E, **Jacobs VR**, Peschel C, Götze KS. [Oncostatin M-mediated regulation of KIT-ligand-induced extracellular signal-regulated kinase signaling maintains hematopoietic repopulating activity of Lin-CD34+CD133+ cord blood cells](#). Stem Cells. 2008 Aug;26(8):2164-72. **IF=7,531**
45. **Oriol B**, Barrio A, Pacheco A, Serna J, Zuzuarregui JL, Garcia-Velasco JA. [Systemic methotrexate to treat ectopic pregnancy does not affect ovarian reserve](#). Fertil Steril. 2008 Nov;90(5):1579-82. **IF=3,168**
46. Oskay-Oezcelik G, Koensgen D, Hindenburg HJ, Klare P, **Schmalfeldt B**, Lichtenegger W, Chekerov R, Al-Batran SE, Neumann U, Sehoul J; Ovarian Cancer Study Group of the North-Eastern Germany Society of Gynecological Oncology (NOGGO). [Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO](#). Anticancer Res. 2008 Mar-Apr;28(2B):1329-34. **IF=1,414**
47. Osorio A, Pollán M, Pita G, Schmutzler RK, Versmold B, Engel C, **Meindl A**, Arnold N, Preisler-Adams S, Niederacher D, Hofmann W, Gadzicki D, Jakubowska A, Hamann U, Lubinski J, Toloczko-Grabarek A, Cybulski C, Debniak T, Llort G, Yannoukakos D, Díez O, Peissel B, Peterlongo P, Radice P, Heikkinen T, Nevanlinna H, Mai PL, Loud JT, McGuffog L, Antoniou AC, Benitez J; CIMBA. [An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers](#). Br J Cancer. 2008 Sep 16;99(6):974-7. **IF=4,635**
48. **Ramser J**, Ahearn ME, Lenski C, Yariz KO, Hellebrand H, von Rhein M, Clark RD, Schmutzler RK, Lichtner P, Hoffman EP, **Meindl A**, Baumbach-Reardon L. [Rare missense and synonymous variants in UBE1 are associated with X-linked infantile spinal muscular atrophy](#). Am J Hum Genet. 2008 Jan;82(1):188-93. **IF=11,092**
49. Ruckhäberle E, Nekolla SG, Ganter C, **Schneider KT**, Peter A, Raidt A, Kovacs L, Brockmeier SJ, Schwaiger M, Oberhoffer R, Papadopoulos NA. [In vivo intrauterine sound pressure and temperature measurements during magnetic resonance imaging \(1.5 T\) in pregnant ewes](#). Fetal Diagn Ther. 2008;24(3):203-10. **IF=0,844**
50. Ruppert C, Mahavadi P, Wygrecka M, Weaver TE, **Magdolen V**, Idell S, Preissner KT, Seeger W, Günther A, Markart P. [Recombinant production of a hybrid plasminogen activator composed of surfactant protein B and low-molecular-weight urokinase](#). Thromb Haemost. 2008 Dec;100(6):1185-92. **IF=3,501**
51. Schiermeier S, **Pildner von Steinburg S**, Thieme A, Reinhard J, Daumer M, Scholz M, Hatzmann W, **Schneider KT**. [Sensitivity and specificity of intrapartum computerised FIGO criteria for cardiotocography and fetal scalp pH during labour: multicentre, observational study](#). BJOG. 2008 Nov;115(12):1557-63. **IF=2,666**
52. **Schmalfeldt B**, **Seifert-Klauss V**, **Paepke S**, **Kiechle M**: Beratung zur HPV-Impfung bei jungen sexuell aktiven Frauen. Geburtshilfe Frauenheilkd 2008;68(1):27-30. **IF=0,502**
53. **Schmidmayr M**, **Magdolen U**, Tübel J, **Kiechle M**, Burgkart R, **Seifert-Klauss V**: Progesteron verstärkt die Differenzierung primärer humaner Osteoblasten in Langzeit-Kulturen. Geburtshilfe Frauenheilkd 2008;68(7):722-728. **IF=0,502**

54. **Schmitt M, Mengele K**, Gkazepis A, Napieralski R, **Magdolen V, Reuning U, Harbeck N**. Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI- 1 in Breast Cancer Tissue: Historical Aspects and Future Prospects. *Breast Care* 2008;3(Suppl 2):3-10. **IF=0,040**
55. **Schneider KT**. [\[What does the obstetrician expect from the internist during prenatal care?\]](#) *Internist (Berl)*. 2008 Jul;49(7):799-804. **IF=0,271**
56. **Seifert-Klauss V**, Kingwell E, Hitchcock CL, Kalyan S, Prior JC. [Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society](#). *Menopause*. 2008 Jan-Feb;15(1):203; author reply 203-4. No abstract available. (Letter to Editor)
57. Sobanski E, Brüggemann D, Alm B, Kern S, Philipsen A, **Schmalzried H**, Hesslinger B, Waschkowski H, Rietschel M. [Subtype differences in adults with attention-deficit/hyperactivity disorder \(ADHD\) with regard to ADHD-symptoms, psychiatric comorbidity and psychosocial adjustment](#). *Eur Psychiatry*. 2008 Mar;23(2):142-9. **IF=1,875**
58. Stemmler HJ, **Mengele K, Schmitt M, Harbeck N**, Laessig D, Herrmann KA, Schaffer P, Heinemann V. [Intrathecal trastuzumab \(Herceptin\) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report](#). *Anticancer Drugs*. 2008 Sep;19(8):832-6. **IF=2,357**
59. Straube S, Voigt M, Briese V, **Schneider KT**, Voigt M. [Weight gain in pregnancy according to maternal height and weight](#). *J Perinat Med*. 2008;36(5):405-12. **IF=1,101**
60. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC Jr, Dowell B, Esteva FJ, Haglund C, **Harbeck N**, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih IeM, Sibley P, Sólétormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP; National Academy of Clinical Biochemistry. [National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers](#). *Clin Chem*. 2008 Dec;54(12):e11-79. **IF=4,803**
61. Vescia S, **Baumgärtner AK, Jacobs VR, Kiechle-Bahat M**, Rody A, Loibl S, **Harbeck N**. [Management of venous port systems in oncology: a review of current evidence](#). *Ann Oncol*. 2008 Jan;19(1):9-15. **IF=4,875**
62. Voigt M, Olbertz D, Fusch C, Krafczyk D, Briese V, **Schneider KT**. [\[The influence of previous pregnancy terminations, miscarriages and still-births on the incidence of babies with low birth weight and premature births as well as a somatic classification of newborns\]](#) *Z Geburtshilfe Neonatol*. 2008 Feb;212(1):5-12. **IF=0,000**
63. Voigt M, Rochow N, Zygmunt M, Straube S, **Schneider KT**, Briese V. [Risks of pregnancy and birth, birth presentation, and mode of delivery in relation to the age of primiparous women](#). *Z Geburtshilfe Neonatol*. 2008 Dec;212(6):206-10. **IF=0,000**
64. Voigt M, Straube S, Zygmunt M, Krafczyk B, **Schneider KT**, Briese V. [Obesity and pregnancy - a risk profile](#). *Z Geburtshilfe Neonatol*. 2008 Dec;212(6):201-5. **IF=0,000**
65. Warm M, Gatermann C, Kates R, Mallmann P, **Paepke S, Harbeck N**, Thomas A. [Postoperative sense of well-being and quality of life in breast cancer patients do not depend on type of primary surgery](#). *Onkologie*. 2008 Mar;31(3):99-104. **IF=1,227**
66. Weirich G, **Mengele K**, Yfanti C, Gkazepis A, Hellmann D, Welk A, Giersig C, Kuo WL, Rosner MR, Tang WJ, **Schmitt M**. [Immunohistochemical evidence of ubiquitous distribution of the metalloendoprotease insulin-degrading enzyme \(IDE: insulysin\) in human non-malignant tissues and tumor cell lines](#). *Biol Chem*. 2008 Nov;389(11):1441-5. **IF=2,840**
67. Yang R, Frank B, Hemminki K, Bartram CR, Wappenschmidt B, Sutter C, **Kiechle M**, Bugert P, Schmutzler RK, Arnold N, Weber BH, Niederacher D, **Meindl A**, Burwinkel B. [SNPs in ultraconserved elements and familial breast cancer risk](#). *Carcinogenesis*. 2008 Feb;29(2):351-5. **IF=5,406**
68. Yfanti C, **Mengele K**, Gkazepis A, Weirich G, Giersig C, Kuo WL, Tang WJ, Rosner M, **Schmitt M**. [Expression of metalloprotease insulin-degrading enzyme insulysin in normal and malignant human tissues](#). *Int J Mol Med*. 2008 Oct;22(4):421-31. **IF=1,847**

\* Autor/-en der Frauenklinik der TUM sind als Contributors des Trials gelistet

**Kumulativer Impaktfaktor für 2008: 323,323**